EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas

BACKGROUND: Squamous cell carcinomas (SCC) account for approximately 30% of non-small cell lung cancer (NSCLC). Current staging methods do not adequately predict outcome for this disease. EMX2 is a homeo-domain containing transcription factor known to regulate a key developmental pathway. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Dongsheng, Li, Hui, Che, Juanjuan, Zhang, Yi, Tolani, Bhairavi, Mo, Minli, Zhang, Hua, Zheng, Qingfeng, Yang, Yue, Cheng, Runfen, Jin, Joy Q., Luh, Thomas W., Yang, Cathryn, Tseng, Hsin-Hui K., Giroux-Leprieur, Etienne, Woodard, Gavitt A., Hao, Xishan, Wang, Changli, Jablons, David M., He, Biao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488446/
https://www.ncbi.nlm.nih.gov/pubmed/26132438
http://dx.doi.org/10.1371/journal.pone.0132134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4488446/
https://www.ncbi.nlm.nih.gov/pubmed/26132438
http://dx.doi.org/10.1371/journal.pone.0132134

Ejemplares similares